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Abstract
Background
Elevated serum uric acid (sUA) concentrations are common in the general population and
are associated with chronic metabolic conditions and adverse clinical outcomes. We evalu-
ated secular trends in the burden of hyperuricaemia from 2006–2014 within the Irish health
system.
Methods
Data from the National Kidney Disease Surveillance Programme was used to determine the
prevalence of elevated sUA in adults, age > 18 years, within the Irish health system. Hyper-
uricaemia was defined as sUA > 416.4 μmol/L in men and > 339.06 μmol/L in women, and
prevalence was calculated as the proportion of patients per year with mean sUA levels
above sex-specific thresholds. Temporal trends in prevalence were compared from 2006 to
2014 while general estimating equations (GEE) explored variation across calendar years
expressed as odds ratios (OR) and 95% Confidence intervals (CI).
Results
From 2006 to 2014, prevalence of hyperuricaemia increased from 19.7% to 25.0% in men
and from 20.5% to 24.1% in women, P<0.001. The corresponding sUA concentrations
increased significantly from 314.6 (93.9) in 2006 to 325.6 (96.2) in 2014, P<0.001. Age-spe-
cific prevalence increased in all groups from 2006 to 2014, and the magnitude of increase
was similar for each age category. Adjusting for baseline demographic characteristics and
illness indicators, the likelihood of hyperuricemia was greatest for patients in 2014; OR 1.45
(1.26–1.65) for men and OR 1.47 (1.29–1.67) in women vs 2006 (referent). Factors associ-
ated with hyperuricaemia included: worsening kidney function, elevated white cell count,
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Conclusions
The burden of hyperuricaemia is substantial in the Irish health system and has increased in
frequency over the past decade. Advancing age, poorer kidney function, measures of nutri-
tion and inflammation, and regional variation all contribute to increasing prevalence, but
these do not fully explain emerging trends.
Introduction
Serum uric acid (sUA) has emerged as an important biomarker of cardiovascular health and a
large body of evidence now incriminates elevated concentrations in the development of several
chronic metabolic conditions, cardiovascular disease, and associated mortality [1–6]. Prospec-
tive epidemiological studies have demonstrated that rising sUA concentrations are indepen-
dently associated with the development of chronic kidney disease, new-onset hypertension,
and type 2 diabetes [3–6]. Moreover, evidence has accumulated that elevated sUA concentra-
tions above conventional thresholds predict future myocardial infarction, stroke and cardio-
vascular death and all-cause mortality [7–9]. Collectively, these studies suggest at the very least
that sUA is an important metabolic and cardiovascular biomarker that merits measurement
and surveillance.
Given the potential contribution of sUA to chronic disease and mortality, periodic surveil-
lance of sUA concentrations at a population level and within health systems is desirable to
evaluate burden and temporal trends [10–12]. A study from the US by Zhu et al found signifi-
cantly higher burden of hyperuricaemia in men and in women in 2007–2008 compared to
1988–1994 that was partially attributed to increasing levels of obesity and hypertension [10]. A
further study from Italy by Trifiro et al covering the period 2005–2009 reported a similar pat-
tern [11]. In contrast, Chuang et al found that mean sUA levels decreased between 1993–1996
and 2005–2008 in Taiwan with a corresponding fall in burden of hyperuricaemia among men
and women [12]. The lack of concordance across studies would suggest that the prevalence of
hyperuricaemia varies substantially worldwide and that country-to-country differences exist
possibly reflecting differences in underlying genetic, dietary and lifestyle factors. There are lim-
ited studies that have described temporal trends in hyperuricaemia among patients who are
captured within the health system [11]. Moreover, even fewer have investigated underlying
reasons for these trends and whether longitudinal patterns in sUA concentrations might be
related to changing demographic and clinical phenotypes.
In view of these knowledge deficits, we explored temporal trends in hyperuricaemia from
2006 to 2014 among patients within the Irish health system. Our primary objective was to
examine patterns in temporal trends and ascertain whether any observed variation might be
explained by changing demographic profiles, clinical measures of health status or geography.
Methods
Dataset
We utilised data from the National Kidney Disease Surveillance System which serves to monitor
trends and outcomes of kidney disease in the Irish health system [13]. The system integrates
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and links health system data from multiple sources across large provincial regions in the Irish
health system through a secure network. The principal data sources include: regional labora-
tory information systems which capture both inpatient and outpatient laboratory tests within
a designated region, dialysis registers which capture incident dialysis; and mortality data files
from the national Central Statistics Office (CSO). We identified all patients with measured
sUA concentrations values from two major health regions; Northwest region (from 2005–
2011) and Midwest region (from 1999–2013), and linked laboratory data records over time
using an EM-algorithm based probabilistic matching strategy [14]. Excluding missing data on
age, sex, and unmatched mortality records, we identified 128,014 patients with linked demo-
graphic, laboratory and outcome data (Fig 1).
Laboratory data
An enzymatic colorimetric method using uricase enzyme on an auto analyzer was used to
measure sUA concentrations during which uric acid is converted to allantoin and H2O2.
Fig 1. Strobe diagram for the retrospective cohort study from 2006–2014. The final dataset captured information on demographic characteristics,
county of residence, primary location of patient supervision, measured laboratory parameters, dialysis indicator variables and death.
https://doi.org/10.1371/journal.pone.0198197.g001
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Serum creatinine was measured using the modified kinetic Jaffe method and creatinine values
were calibrated to be traceable to an isotope dilution mass spectrometry (IDMS) reference
measurement procedure to ensure standardization. Serum creatinine values were used to esti-
mate glomerular filtration rate (eGFR) in ml/min per 1.73 m2 using the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) [15]. Chronic Kidney Disease (CKD) was
defined according to the Kidney Disease Dialysis Quality Outcome Initiative (KDOQI) guide-
lines based on eGFR measurements. Data was captured on an extensive list of laboratory mea-
sures including indicators of inflammation (c-reactive protein, ESR, white cell count and
subtypes), nutrition (serum albumin and total protein), bone biomarkers (serum calcium and
phosphate), and haemoglobin. The location of medical supervision was defined as the location
where the first uric acid test was ordered by the supervising health professional and categorized
as; inpatient location (IP), outpatient department (OP), general practice (GP) and emergency
room (ER). County of residence was available for each patient and allowed us to classify
patients by geography. The principal counties served by the Northwest region of Ireland
included Donegal, Sligo, Leitrim and Roscommon while those served by the Midwest region
included Limerick, Clare and Tipperary.
Definition of hyperuricaemia
Hyperuricaemia was defined as sUA > 416.4 μmol/L in men and> 339.06 μmol/L in women
respectively. These values were chosen based on the laboratory definition as utilised in
NHANES 3 [10] and have been widely used in the literature. Our definition was based on a
single sUA for each patient within a specific year. For patients with more than one sUA value
per year, the mean sUA was determined. The values of sUA are reported in micromoles per
litre and can be converted to milligrams per decilitre by dividing by 59.48.
Statistical analysis
Descriptive statistics were calculated for continuous variables (reported as mean values and
standard deviations or median and IQR where appropriate) and categorical variables (reported
as numbers and percentages). Differences between categories were evaluated using the Kruskal
Wallis test, Fisher’s Exact test or the χ2 test, as appropriate.
The prevalence of hyperuricemia was calculated as the proportion of patients within a cal-
endar year with a mean sUA; > 416.4 μmol/L in men and> 339.06 μmol/L in women respec-
tively among all patients with a measured sUA concentration. Prevalence was calculated
according to age and sex distributions, location of medical supervision, country of residence,
and among clinical subgroups according to eGFR, and glycosylated haemoglobin ( 6.5% vs
less). Temporal trends in prevalence of hyperuricaemia were determined and compared across
years using chi-square proportional trend test.
General Estimating Equations (GEE) with a logit link function for binary outcomes and an
exchangeable correlation structure were fitted to explore the associations of demographic, clin-
ical and geographic factors with the prevalence of hyperuricaemia. The sandwich estimator
was used to adjust the standard errors of the estimated coefficients to account for the longitu-
dinal aspect of the design. A marginal (‘population-average’) regression model was selected to
analyse the average prevalence associated with each characteristic while accounting for within-
subject correlation over time. In a series of sequentially adjusted models we assessed whether
the association of calendar year with hyperuricaemia could be explained by demographic, clin-
ical or geographic factors. Calendar year was modelled primarily as a categorical variable with
2006 as referent. A final multivariable model was constructed to identify the relative contribu-
tions of demographic, clinical and health system factors with the presence of hyperuricemia,
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thereby clarifying the temporal relationship. The associations of explanatory factors with
hyperuricaemia were represented by adjusted odds-ratios (AOR) and 95% CI. Wald statistics
from the corresponding generalized estimating equations were used to test for the significance
of these associations. The interactions between age and sex were tested in multivariable models
for risk of hyperuricaemia.
The correlation information criterion (CIC) as proposed by Hin and Wang was used to
determine correlation structures for repeated measurements [16]. The discriminative capacity
of the models was determined by the Area Under the Curve (AUC) value of the Receiver Oper-
ating Characteristic (ROC) curves. All analyses were performed with the geepack, pROC pack-
ages using R statistical software.
Sensitivity analyses
A set of sensitivity analyses explored the robustness of our observations. First, we examined
to what extent our estimates were influenced by lowering our threshold definition of hyper-
uricaemia to sUA > 356.8 μmol/L (6.0 mg/dl) for both men and women based on evidence
derived from expert panels ascertaining risk thresholds [17,18]. Second, we considered
the impact of sUA > 416.4 μmol/L (7.0 mg/dl) for men and women, a threshold value
above the supersaturation point of sUA. Finally, we substituted the mean for the median
sUA and repeated the entire analysis to determine whether this would materially alter our
estimates.
Ethics approval
Ethical approval and a waiver of informed consent for the study were granted by the Ethics
Committee at University Hospital Limerick. All patient records were fully anonymised prior
to data analysis which was conducted at the Data Coordinating Centre (DCC).
Results
Baseline characteristics of the study cohort
There were 128,014 individuals, age 18 years or older, who had valid sUA measurements from
2006–2014. Of these 25,497 (19.9%) were defined as hyperuricaemic at first entry into the
health system. The mean age was 52.4 (17.7) years, and 51. 5% were women (Table 1). Patients
with hyperuricaemia were significantly older; predominantly men, had higher serum creati-
nine values, inflammatory markers, and had significantly lower estimated GFR values com-
pared to those without hyperuricaemia (all P< 0.001).
Prevalence of hyperuricaemia between 2006–2014
Table 2 shows the temporal trends in prevalence of hyperuricaemia from 2006 to 2014. Overall
prevalence of hyperuricaemia increased from 20.1% in 2006 to 24.5% in 2014 and this pattern
was present for both men and women (Fig 2, P<0.001 for each). Age-specific prevalence was
observed to increase in all groups from 2006 to 2014, and the magnitude of increase was simi-
lar for each age category. Although the overall prevalence of hyperuricaemia was higher in
men than women, this was not consistent across age categories as shown in Fig 3. From young
adulthood to middle-age, the prevalence of hyperuricaemia was higher in men than women;
however, after the age of 60 years, the prevalence of hyperuricaemia rose sharply in women
and far exceeded that of men.
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Table 1. Patient characteristics at baseline by presence or absence of hyperuricaemia1.
Variable N No Hyperuricaemia Hyperuricaemia P-value
Count (%) 128,014 102,517 (80.1) 25,497 (19.9)
Age [Mean(SD)] 128,014 51.0 (17.3) 58.1 (18.1) <0.001
Sex
% Female 65,862 52.14 48.69
% Male 62,152 47.86 51.31 <0.001
Age Group (n, %)
18–39 years 34,687 29.13 18.9
40–59 years 46,337 37.42 31.26
60–80 years 39,440 28.94 38.31
>80 years 7,550 4.50 11.52 <0.001
County of Residence (n, %)
Donegal 26,177 21.58 15.9
Sligo 18,140 14.76 11.8
Leitrim 7,971 6.57 4.86
Roscommon 796 0.63 0.57
Limerick 37,425 27.89 34.63
Clare 12,818 9.69 11.31
Tipperary 6,255 4.58 6.12
Other Counties 18,432 14.3 14.81 <0.001
Location of Medical Supervision2
Emergency Room (ER) 4,769 3.74 4.55
General Practice (GP) 86,951 71.81 68.73
Inpatient (IP) 15,816 12.57 14.43
Outpatient (OP) 14,608 11.88 12.29 <0.001
Laboratory Variables3
Measures of Kidney Function
Creatinine (μmol/L) 108,444 71.7 (21.0) 84.0 (30.3) <0.001
eGFR (ml/min/1.73m2) 108,444 95.0 (26.8) 78.9 (38.3) <0.001
Urea (mmol/L) 110,664 5.6 (2.2) 6.7 (3.1) <0.001
eGFR Category4
eGFR90 61,736 62.16 35.39
eGFR 60–89 36,798 32.79 38.62
eGFR 30–59 8,585 4.65 21.35
eGFR 15–29 1,056 0.28 3.83
eGFR < 15 269 0.11 0.81 <0.001
Measures of Inflammation
C-Reactive Protein (mg/L) 15,083 3.0 (4.0) 5.0 (9.9) <0.001
ESR (mm/hr) 41,854 10.2 (14.0) 14.8 (21.6) <0.001
White blood count (x109/L) 100,381 6.7 (4.2) 7.4 (4.0) <0.001
Lymphocyte count(x109/L) 98,492 1.7 (1.0) 1.7 (1.0) 0.001
Neutrophil count (x109/L) 99,951 3.9 (3.2) 4.4 (3.2) <0.001
Measures of Nutrition
Serum Albumin (g/L) 95,613 38.2 (5.1) 37.4 (5.5) <0.001
Total protein (mmol/L) 89,594 68.3 (5.9) 69.0 (6.6) <0.001
Measures of Bone Metabolism
Serum Calcium (mmol/L) 66,251 2.3 (0.1) 2.3 (0.1) <0.001
Serum Phosphate (mmol/L) 56,378 1.1 (0.2) 1.2 (0.3) <0.001
(Continued)
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Prevalence of hyperuricaemia between 2006–2014: Regional and county
variation
The prevalence of hyperuricaemia varied significantly across regions within the health system.
In 2006, the prevalence was highest in the Midwest region (Counties of Limerick, Clare and
Tipperary) at 22.1% compared to 17.7% in the Northwest region (Counties of Donegal, Sligo,
Leitrim and Roscommon). Increases in prevalence were observed in each region over time but
the relative differences persisted. At the county level, significant increases in the prevalence of
hyperuricaemia were observed over time except in county Tipperary.
Prevalence of hyperuricaemia by level of kidney function and by
glycosylated haemoglobin (HbA1c)
The prevalence of hyperuricaemia increased significantly with worsening renal function, from
12.2% in patients with eGFR> 90ml/min to 63.9% in patients with eGFR< 15ml/min. The
corresponding mean sUA levels increased from 297.2 (81.5) μmol/L in eGFR category 1 to
391.8 (146.7) μmol/L in eGFR category 5, although levels were highest for patients in eGFR
category 4 at 450.3 (129.8) μmol/L. Among patients with mild–moderate kidney impairment
(correlating with eGFR categories 1–3), significant trends of increasing prevalence were
observed from 2006–2014 as shown in Fig 4. In contrast, among patients with severe kidney
impairment (correlating with eGFR categories 4–5), the prevalence remained relatively stable
over the same period. At baseline, the prevalence of hyperuricaemia was similar among
patients with or without good glycaemic control (28.3% and 28.5% for HbA1c < 6.5%
vs 6.5% respectively). However, from 2006 to 2014, the burden of hyperuricaemia among
patients with HbA1c 6.5% increased by 7.5% from 24.0% (95% CI: 20.6%-27.4%) to 31.5%
(95% CI: 29.4%–33.6%), P< 0.001.
Table 1. (Continued)
Variable N No Hyperuricaemia Hyperuricaemia P-value
Metabolic Biomarkers
Serum Uric Acid (umol/L) [Mean(SD)] 128,014 280.7 (65.0) 448.1 (80.5) <0.001
Haemoglobin (g/dl) 100,384 13.3 (1.8) 13.3 (2.0) <0.001
Ferritin (ng/ml) 38,123 120.2 (264.5) 180.0 (259.1) <0.001
Glucose (mmol/L) 23,385 5.0 (1.0) 5.2 (1.2) <0.001
Serum Potassium (mmol/L) 89,446 4.3 (0.5) 4.4 (0.5) <0.001
HbA1c (%) 10,530 5.8 (1.4) 6.0 (1.1) <0.001
Glycaemic Control (n, %)
HbA1c <6.5% 7,546 71.7 71.5
HbA1c6.5% 2,984 28.3 28.5 0.879
Lipids
Total Cholesterol (mmol/L) 46,250 5.1 (1.1) 5.2 (1.2) <0.001
Triglyceride (mmol/L) 50,536 1.2 (0.9) 1.6 (1.2) <0.001
High Density Lipoprotein (mmol/L) 9,430 1.3 (0.4) 1.2 (0.4) <0.001
Low Density Lipoprotein (mmol/L) 31,359 3.2 (0.9) 3.3 (1.0) <0.001
1 Hyperuricaemia was defined as sUA > 416.4 μmol/L in men and > 339.06 μmol/L in women respectively based on the laboratory definition from NHANES 3 [10].
2 Location of medical supervision refers to the location of patient when the laboratory test was conducted.
3 Values are reported as median with interquartile range
4 eGFR: Estimated glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative (CKD-EPI) equation [15]
https://doi.org/10.1371/journal.pone.0198197.t001
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Table 2. Temporal trends in prevalence of hyperuricaemia in the Irish health system.
Variable 2006 2007 2008 2009 2010 2011 2012 2013 2014 P-value
Events of hyperuricaemia
Uric Acid [Mean(SD)1]
4776
314.6
(93.9)
5425
316.0
(93.2)
5760
319.3
(93.5)
5796
322.0
(93.9)
5852
321.6
(92.4)
6246
323.1
(92.9)
6603
322.9
(93.8)
7038
324.8
(94.9)
8289
325.6
(96.2)
<0.001
Age group
18–39 years 13.7
(12.8, 14.7)
13.5
(12.6, 14.4)
15.2
(14.2, 16.1)
16.7
(15.7, 17.7)
15.4
(14.4, 16.4)
15.9
(14.9, 16.8)
16.2
(15.3, 17.2)
17.2
(16.3, 18.2)
18.6
(17.6, 19.5)
<0.001
40–59 years 16.5
(15.7, 17.3)
17.6
(16.8, 18.3)
18.0
(17.3, 18.8)
19.1
(18.3, 19.9)
18.7
(17.9, 19.4)
18.5
(17.7, 19.2)
19.3
(18.5, 20.1)
20.4
(19.6, 21.2)
20.2
(19.5, 21)
<0.001
60–80 years 24.1
(23.2, 25)
23.9
(23.1, 24.8)
25.0
(24.2, 25.9)
25.5
(24.6, 26.4)
25.1
(24.2, 25.9)
26.6
(25.8, 27.5)
26.3
(25.5, 27.2)
27.0
(26.2, 27.8)
27.7
(26.9, 28.4)
<0.001
>80 years 39.2
(36.8, 41.6)
38.2
(36, 40.4)
39.8
(37.6, 42)
39.9
(37.6, 42.3)
40.8
(38.5, 43.1)
42.3
(40.1, 44.6)
41.7
(39.5, 43.8)
40.2
(38.1, 42.3)
43.0
(41.1, 45)
0.001
County of Residence
Donegal 15.7
(14.6, 16.9)
16.6
(15.5, 17.6)
18.5
(17.4, 19.6)
19.4
(18.3, 20.5)
19.2
(18.1, 20.3)
20
(18.9, 21.1)
20.5
(19.5, 21.6)
20.6
(19.5, 21.6)
20.8
(19.8, 21.8)
<0.001
Sligo 21.0
(19.7, 22.2)
18.9
(17.7, 20)
18.2
(17.1, 19.3)
19.8
(18.6, 21)
18.1
(17, 19.3)
22.6
(21.3, 24)
21
(19.7, 22.4)
21
(19.6, 22.5)
23.9
(22.4, 25.4)
<0.001
Leitrim 16.2
(14.5, 17.9)
15.4
(13.8, 16.9)
15.4
(13.9, 16.9)
17.2
(15.6, 18.9)
15.3
(13.6, 17)
19.2
(17.5, 21)
18.3
(16.8, 19.9)
16.3
(14.6, 17.9)
19.2
(17.4, 21)
0.001
Roscommon 16.7
(11, 22.3)
14.0
(9.2, 18.8)
14.0
(8.9, 19.1)
14.3
(9.1, 19.5)
17.9
(12.2, 23.6)
17.0
(11.6, 22.5)
22.3
(16, 28.6)
22.2
(15.5, 28.8)
25.2
(17.8, 32.6)
0.001
Limerick 22.6
(21.6, 23.5)
24.1
(23.2, 25)
26.2
(25.3, 27.2)
26.0
(25.1, 27)
25.5
(24.6, 26.4)
24.8
(23.9, 25.7)
25.8
(24.9, 26.6)
26.8
(25.9, 27.7)
27.9
(27.1, 28.8)
<0.001
Clare 21.2
(19.5, 22.8)
23.0
(21.3, 24.6)
23.5
(21.8, 25.2)
24.3
(22.6, 26)
23.6
(21.9, 25.2)
23.3
(21.8, 24.7)
24.1
(22.5, 25.7)
24.9
(23.4, 26.4)
25.3
(23.8, 26.8)
<0.001
Tipperary 22.5
(18.6, 26.5)
24.9
(21.7, 28.1)
25.3
(21.8, 28.7)
28.3
(24.9, 31.6)
23.6
(20.9, 26.3)
23.3
(20.7, 25.9)
24.2
(21.8, 26.7)
26.3
(24.3, 28.4)
25.5
(24, 26.9)
0.383
Other Counties 19.3
(17.9, 20.7)
18.8
(17.5, 20.1)
20.4
(19.1, 21.7)
21.1
(19.7, 22.5)
23.2
(21.8, 24.6)
22.2
(20.9, 23.6)
22.8
(21.4, 24.1)
24.5
(23.2, 25.8)
23.5
(22.4, 24.5)
<0.001
Hospital region
Midwest 22.1
(21.4, 22.9)
23.4
(22.7, 24.1)
25.1
(24.4, 25.8)
25.4
(24.7, 26.1)
25.0
(24.3, 25.7)
24.1
(23.5, 24.8)
25.0
(24.3, 25.6)
26.0
(25.4, 26.7)
26.1
(25.5, 26.7)
<0.001
Northwest 17.7
(17, 18.5)
17.0
(16.3, 17.6)
17.6
(16.9, 18.2)
18.8
(18.1, 19.4)
18.0
(17.3, 18.7)
20.6
(19.9, 21.3)
20.2
(19.5, 20.9)
20.0
(19.3, 20.8)
21.5
(20.7, 22.2)
<0.001
Location of Medical
Supervision2
Emergency Room (ER) 24.0
(20.4, 27.5)
27.1
(23.7, 30.6)
27.8
(24.5, 31.2)
25.7
(22.6, 28.8)
22.5
(19.7, 25.4)
22.3
(19.6, 25)
26.6
(23.8, 29.5)
24.2
(21.1, 27.2)
23.6
(20.8, 26.5)
0.187
General Practice (GP) 19.3
(18.7, 19.9)
19.6
(19, 20.2)
20.7
(20.1, 21.3)
21.8
(21.2, 22.4)
21.8
(21.2, 22.5)
22.4
(21.8, 23)
22.1
(21.5, 22.7)
23.4
(22.8, 24)
23.8
(23.3, 24.3)
<0.001
Inpatient (IP) 22.8
(21.3, 24.2)
22.6
(21.3, 23.9)
23.0
(21.5, 24.4)
23.2
(21.7, 24.7)
22.3
(20.9, 23.8)
23.0
(21.6, 24.5)
23.2
(21.8, 24.7)
22.5
(21.1, 23.9)
24.5
(23, 26)
0.237
Outpatient (OP) 22.0
(20.3, 23.7)
24.2
(22.6, 25.8)
25.2
(23.7, 26.6)
24.7
(23.3, 26.1)
22.8
(21.5, 24.1)
24.0
(22.7, 25.3)
26.7
(25.3, 28)
27.3
(25.9, 28.6)
29.3
(27.9, 30.6)
<0.001
Glycosylated Haemoglobin3
HbA1c <6.5% 27.8
(25.4,30.2)
23.5
(21.5,25.5)
26.9
(24.9,28.9)
29.3
(27.1,31.6)
27.5
(25.1,29.9)
26.0
(24.2,27.7)
24.0
(22.4,25.5)
25.7
(24.2,27.1)
26.0
(24.9,27.1)
0.218
HbA1c6.5% 24.0
(20.6,27.4)
25.7
(22.6,28.7)
26.2
(23.5,28.9)
27.1
(24.3,29.8)
25.5
(22.6,28.3)
28.5
(26.1,31)
31.0
(28.5,33.4)
34.1
(31.6,36.7)
31.5
(29.4,33.6)
<0.001
eGFR Category 4
eGFR 90 11.5
(10.8, 12.1)
11.1
(10.5, 11.7)
12.9
(12.3, 13.5)
13.8
(13.2, 14.5)
13.5
(12.9, 14.1)
13.6
(13, 14.1)
13.8
(13.2, 14.4)
14.8
(14.2, 15.4)
15.3
(14.7, 15.9)
<0.001
(Continued)
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Table 2. (Continued)
Variable 2006 2007 2008 2009 2010 2011 2012 2013 2014 P-value
eGFR 60–89 19.2
(18.3, 20.1)
20.3
(19.5, 21.2)
22.8
(21.9, 23.7)
22.7
(21.8, 23.6)
23.0
(22.1, 23.9)
24.8
(23.9, 25.7)
23.7
(22.9, 24.6)
25
(24.2, 25.9)
25.1
(24.3, 25.9)
<0.001
eGFR 30–59 48.3
(46.1, 50.6)
48.4
(46.3, 50.4)
54.8
(52.8, 56.9)
54.4
(52.4, 56.3)
54.3
(52.4, 56.3)
54.9
(53, 56.8)
55.9
(54.1, 57.7)
53.8
(52, 55.5)
54.8
(53.2, 56.4)
<0.001
eGFR 15–29 75.2
(69.8, 80.6)
66.8
(61.5, 72.1)
73.0
(67.9, 78.1)
69.2
(64.3, 74.2)
66.2
(61.4, 71.1)
70.0
(65.5, 74.4)
70.5
(66.2, 74.8)
68.9
(64.8, 73)
67.7
(63.7, 71.7)
0.209
eGFR <15 59.2
(48.2, 70.3)
57.3
(46.1, 68.5)
48.7
(37.3, 60)
45.8
(35.1, 56.5)
38.0
(27.3, 48.7)
43.2
(32.4, 54)
45.6
(33.8, 57.4)
47.3
(35.9, 58.7)
48.9
(38.8, 59.1)
0.085
1 Prevalence of hyperuricemia was calculated as the proportion of patients within a calendar year with a mean sUA; > 416.4 μmol/L in men and > 339.06 μmol/L in
women with 95% Confidence Intervals
2 Location of medical supervision refers to the location of patient when the laboratory test was conducted.
3 Haemoglobin A1c reported according to the Diabetes Control and Complications Trial (DCCT). Values reported as International Federation of Clinical Chemistry
(IFFC) were converted to DCCT using the equation: IFCC-HbA1c (mmol/mol) = [DCCT-HbA1c (%)−2.15] x 10.929.
4 eGFR: Estimation of glomerular filtration rate (ml/min per 1.73 m2) was based on the Chronic Kidney Disease Collaborative (CKD-EPI) Equation [15]
https://doi.org/10.1371/journal.pone.0198197.t002
Fig 2. Temporal trends in the prevalence of hyperuricaemia by sex in the health system. Error bars represent 95% CI’s calculated form the direct
method.
https://doi.org/10.1371/journal.pone.0198197.g002
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Patient-level factors associated with hyperuricaemia
Table 3 describes the relationship of demographic, clinical and geographic factors with hyper-
uricaemia within the health system. The likelihood of hyperuricaemia increased with advanc-
ing age category, multivariable OR, 1.27 (1.15–1.42), P< 0.01 for oldest vs youngest. A
significant age-sex interaction (P<0.001) indicated that the likelihood of hyperuricaemia dif-
fered between men and women across age categories. Adjusting for calendar year only, the
odds ratio of hyperuricaemia was significantly higher in older women than in older men. In
the fully adjusted model, the likelihood of hyperuricaemia increased with age in women but
not in men (Fig 5A).
Patients with the lowest levels of kidney function (eGFR categories 4 and 5) experienced the
greatest likelihood of hyperuricaemia, OR, 10.92 (8.99–13.25) and 6.33 (4.58–8.74) in men and
OR, 21.08 (16.99–26.16) and 8.66 (5.76–13.12) in women respectively as shown in Fig 5b. The
adjusted OR of hyperuricaemia increased with each doubling of white cell count. Similarly,
the adjusted OR of hyperuricaemia increased with rising serum phosphate and serum calcium
concentrations. Increases in total serum protein concentrations were positively associated
with hyperuricaemia, while increases in serum albumin concentrations exhibited a negative
Fig 3. Temporal trends in the prevalence of hyperuricaemia by age and sex in the Irish health system. Error bars represent 95% CI’s calculated form
the direct method.
https://doi.org/10.1371/journal.pone.0198197.g003
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Fig 4. Temporal trends in the prevalence of hyperuricaemia by level of kidney function. (A) Illustrates the distribution of
serum uric acid by eGFR category among men and women, the dashed line represents the respective threshold for
hyperuricaemia. (B) Temporal trends in prevalence of hyperuricaemia in the health system from 2006–2014 by eGFR category.
https://doi.org/10.1371/journal.pone.0198197.g004
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Table 3. Factors associated with prevalent cases of hyperuricaemia from 2006–2014 in the Irish health system.
Variables Unadjusted Robust SE P-value Final Multivariable Model1 Robust SE P-value
Age Group
18–39 years 1.00 1.00
40–59 years 1.21 (1.17, 1.26) 0.018 0.000 1.12 (1.03–1.2) 0.039 0.005
60–80 years 1.75 (1.69, 1.81) 0.018 0.000 1.09 (1.01–1.19) 0.042 0.034
>80 years 3.12 (2.96, 3.28) 0.026 0.000 1.27 (1.15–1.42) 0.054 <0.001
Gender
Women 1.00 1.00
Men 1.05 (1.02, 1.07) 0.013 0.000 0.77 (0.73–0.81) 0.027 <0.001
County of Residence
Donegal 1.00 1.00
Sligo 1.20 (1.02–1.42) 0.085 0.029 1.03 (0.94–1.12) 0.044 0.532
Leitrim 1.05 (0.98–1.11) 0.032 0.157 0.95 (0.85–1.06) 0.056 0.375
Roscommon 1.77 (1.66–1.88) 0.032 0.000 1.09 (0.83–1.44) 0.142 0.544
Limerick 1.76 (1.69–1.82) 0.020 0.000 1.34 (1.24–1.44) 0.038 <0.001
Clare 1.66 (1.58–1.75) 0.025 0.000 1.15 (1.04–1.28) 0.053 0.007
Tipperary 1.14 (1.08–1.19) 0.024 0.000 1.36 (1.21–1.53) 0.061 <0.001
All other counties 1.48 (1.41–1.54) 0.023 0.000 1.22 (1.13–1.33) 0.043 <0.001
Location of Medical Supervision
Emergency Room (ER) (Reference) 1.00 1.00
General Practice (GP) 0.93 (0.89–0.99) 0.027 0.012 1.17 (1.06–1.28) 0.048 0.001
Inpatient (IP) 1.02 (0.96–1.07) 0.028 0.586 1.12 (1.02–1.22) 0.048 0.024
Outpatient (OP) 1.00 (0.95–1.06) 0.029 0.995 1.18 (1.07–1.30) 0.048 0.001
Laboratory Variables
GFR Category (ml/min/1.73m2)
eGFR > = 90 1.00 1.00
eGFR 60–89 1.89 (1.84–1.95) 0.014 <0.001 2.12 (2.01–2.24) 0.027 <0.001
eGFR 30–59 5.93 (5.70–6.17) 0.020 <0.001 8.03 (7.43–8.68) 0.039 <0.001
eGFR 15–29 12.20 (11.08–13.43) 0.049 <0.001 14.93 (12.98–17.17) 0.071 <0.001
eGFR <15 6.83 (5.65–8.25) 0.097 <0.001 7.58 (5.91–9.73) 0.127 <0.001
<0.001
Inflammatory markers <0.001
Log 2(White blood count) 1.23 (1.2, 1.25) 0.010 <0.001 1.20 (1.16–1.24) 0.016 <0.001
Serum Albumin (per 1 g/L increase) 0.99 (0.98, 0.99) 0.001 <0.001 0.99 (0.98–0.99) 0.003 <0.001
Nutritional/Metabolic Markers
Total protein (mmol/L) 1st (<64.5) 0.96 (0.93–1.00) 0.017 0.031 0.81 (0.76–0.85) 0.028 <0.001
Total protein (mmol/L) 2nd (64.5–68.7) (Reference) 1.00 1.00
Total protein (mmol/L)3rd (68.0–71.3) 1.10 (1.07, 1.13) 0.015 <0.001 1.14 (1.08–1.20) 0.026 <0.001
Total protein (mmol/L) 4th (>71.3) 1.30 (1.26, 1.35) 0.017 <0.001 1.36 (1.29–1.44) 0.029 <0.001
Serum Calcium (mmol/L) 1st (<2.25) 1.04 (1.00–1.08) 0.019 0.039 1.02 (0.96–1.07) 0.028 0.578
Serum Calcium (mmol/L) 2nd (2.25–2.31) (Reference) 1.00 1.00
Serum Calcium (mmol/L) 3rd (2.31–2.38) 1.11 (1.07–1.15) 0.017 <0.001 1.09 (1.04–1.15) 0.026 0.001
Serum Calcium (mmol/L) 4th (>2.38) 1.29 (1.25–1.34) 0.019 <0.001 1.17 (1.1–1.23) 0.029 <0.001
<0.001
Serum Phosphate (per 1 mmol/L increase) 1.42 (1.33–1.53) 0.037 <0.001 1.14 (1.04–1.26) 0.051 0.008
Haemoglobin (g/dl) 1st <12.1 1.15 (1.1, 1.19) 0.018 <0.001 0.96 (0.91–1.02) 0.031 0.205
Haemoglobin (g/dl) 2nd 12.1–13.3 (Reference) 1.00 1.00
Haemoglobin (g/dl) 3rd 13.3–14.44 1.05 (1.02, 1.09) 0.017 0.002 1.13 (1.07–1.19) 0.029 <0.001
Haemoglobin (g/dl) 4th >14.44 1.2 (1.16, 1.24) 0.018 <0.001 1.42 (1.33–1.52) 0.034 <0.001
(Continued)
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association. Patients with haemoglobin values in the highest quartile groups experienced the
highest OR of hyperuricaemia compared to the referent group (2nd quartile, haemoglobin
12.1–13.3 g/l).
Geography and location of medical supervision with hyperuricaemia
The likelihood of hyperuricaemia varied significantly by county of residence. For example,
male patients from Limerick county, OR, 1.33 (1.20–1.48) and Tipperary, OR, 1.34 (1.14–1.58)
experienced significantly higher odds of hyperuricaemia compared to the referent county
Donegal. The likelihood of hyperuricaemia was found to vary by location of medical supervi-
sion with a higher likelihood of hyperuricaemia found in all clinical settings compared to
patients tested in the emergency room.
Temporal trends in hyperuricaemia from 2006–2014
In univariate analysis, the OR of hyperuricaemia increased with successive calendar years as
shown in Table 3 and Fig 6. With adjustment for confounding; patients who entered the health
system in 2014 were significantly more likely to have hyperuricaemia compared to those in
2006 (referent), OR, 1.44 (1.31–1.58), P<0.001. This pattern of growth was consistent for men
and women. Modelled as a continuous variable, the likelihood of hyperuricaemia increased by
an average of 4% per year (95% CI 1.03–1.05), following adjustment. The final model had a c-
statistic of 0.75 indicating good discrimination. In extended models (models 5 and 6), where
we further adjusted for serum cholesterol, triglycerides and glycosylated haemoglobin, the pat-
tern of association remained largely unchanged (Table 4).
Sensitivity analysis
The robustness of our findings was assessed in three sets of sensitivity analyses. First, using a
lower sUA threshold of>356.8 mmol/l (6.0 mg/dl) based on EULAR targets. As expected, we
Table 3. (Continued)
Variables Unadjusted Robust SE P-value Final Multivariable Model1 Robust SE P-value
Serum Potassium (mmol/L) 1st (<4.07) 0.94 (0.90–0.97) 0.018 <0.001 1.03 (0.97–1.09) 0.028 0.337
Serum Potassium (mmol/L) 2nd (4.07–4.3) (Reference) 1.00 1.00
Serum Potassium (mmol/L) 3rd (4.3–4.67) 1.07 (1.03–1.11) 0.017 <0.001 1.00 (0.95–1.05) 0.026 0.967
Serum Potassium (mmol/L) 4th (>4.67) 1.15 (1.11–1.19) 0.018 <0.001 0.96 (0.91–1.01) 0.027 0.096
Calendar year
2006 (Referent Year) 1.00 1.00
2007 1.03 (0.99–1.07) 0.021 0.199 1.07 (0.99–1.16) 0.042 0.109
2008 1.14 (1.09–1.19) 0.021 <0.001 1.37 (1.26–1.48) 0.041 <0.001
2009 1.16 (1.11–1.21) 0.022 <0.001 1.38 (1.27–1.49) 0.041 <0.001
2010 1.12 (1.08–1.17) 0.022 <0.001 1.35 (1.24–1.46) 0.042 <0.001
2011 1.17 (1.12–1.22) 0.022 <0.001 1.47 (1.35–1.59) 0.042 <0.001
2012 1.15 (1.10–1.20) 0.022 <0.001 1.47 (1.35–1.61) 0.046 <0.001
2013 1.18 (1.13–1.23) 0.022 <0.001 1.35 (1.23–1.47) 0.046 <0.001
2014 1.23 (1.18–1.28) 0.022 <0.001 1.44 (1.31–1.58) 0.047 <0.001
1Covariates for adjustment in the final multivariate model included: age group, sex, GFR category, county of residence, location of medical supervision, laboratory
measures of illness (including haemoglobin, serum albumin, white blood cell count, serum potassium, serum calcium and serum phosphate concentrations) and
calendar year.
https://doi.org/10.1371/journal.pone.0198197.t003
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demonstrated a higher prevalence of hyperuricaemia in men across successive years but the
pattern of change that were similar to that from the main analysis Fig 7A. The association
between calendar year and the likelihood of hyperuricaemia in men mirrored that of the pri-
mary analysis with an adjusted OR 1.45 (1.26–1.65), p<0.001 for hyperuricaemia in 2014 ver-
sus the referent year, 2006. Secondly, using a higher threshold value of UA >416.4 mmol/l (7.0
mg/dl), the prevalence of hyperuricaemia was correspondingly lower in women as shown in
Fig 7B, but again this pattern of association mirrored that of the original analysis with an
adjusted OR 1.40 (1.22–1.62), p<0.001 for 2014 versus referent year. Finally, on substituting
the median for the mean sUA concentration, the same qualitative trends were observed for
both men and women and are illustrated in Fig 7C and 7D.
Fig 5. Forest plot of adjusted odds ratio of hyperuricaemia stratified by sex. Covariates for adjustment include: age group, eGFR CKD-stage in
categories, county of residence, location of medical supervision, laboratory measures of illness (haemoglobin, serum albumin, white blood cell count,
serum potassium, serum calcium and serum phosphate concentration) and calendar year with referent 2006. (A) Illustrates odds ratios for all covariates
except CKD stage which is illustrated separately in (B).
https://doi.org/10.1371/journal.pone.0198197.g005
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Discussion
In this large representative sample of patients within the Irish health System, we observed a
substantial burden of hyperuricaemia and a pattern of increasing prevalence from 2006 to
2014. Overall, 20.1% of adult patients within the health system, men and women, were classi-
fied as having hyperuricaemia, a figure that increased to 24.5% in 2014. The net growth in
prevalence of hyperuricaemia was 4.4% over the 9-year period and this pattern was consistent
across health region, location of medical supervision, and across county of residence. Preva-
lence estimates were highest among elderly patients and those with severely impaired kidney
function. Multivariable modelling found that the rise in annual prevalence was not accounted
for by measured demographic characteristics, indicators of health status, or location of medical
supervision. These findings collectively suggest that the burden of hyperuricaemia, a risk factor
for gout and a risk marker for several metabolic conditions, is increasing in the Irish health
system.
Uric acid, a metabolic waste product of purine metabolism, has been implicated in the
genesis of several chronic medical conditions including gout, chronic kidney disease, hyper-
tension, diabetes and death [2–9,11]. A fundamental requirement of any health system is
surveillance of risk especially risk factors or potential risk factors that contribute to chronic
disease, morbidity and mortality. Most published studies on hyperuricaemia prevalence
to-date have based their analysis on national surveys, and therefore have not specifically
Fig 6. Univariable and multivariable odds-ratio (OR) for hyperuricaemia across calendar years in the Irish health system. In the multivariate
model, covariates for adjustment include: age group, sex, eGFR CKD-stage in categories, county of residence, location of medical supervision,
laboratory measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium, serum calcium and serum phosphate
concentrations) and calendar year with referent 2006. P<0.001 for association of calendar year with 2006 as referent.
https://doi.org/10.1371/journal.pone.0198197.g006
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addressed risk factor burden within the health system [10,12]. Moreover, analysis of country-
specific trends has yielded conflicting results [10–12]. Data form the NHANES surveys in the
US found that the prevalence of hyperuricaemia increased by 3.2% between 1988–1994 and
2007–2008. Similarly, data from the Health Search/CSD data base in Italy yielded a growth
rate of 3.4% over a much shorter time span, 2005 to 2009. In contrast, results from consecutive
Nutrition and Health Surveys in Taiwan (NAHSIT), covering the periods 1993–1996 to 2005–
2008, have clearly shown a fall in prevalence, 3.3% in men and a remarkable 7.0% in women.
Our results are concordant with findings from the US and Italian studies where hyperuricae-
mia increased by 4.4% over a 10 year-period and mean sUA concentrations increased from
314.6 to 325.6 μmol/L. We considered that the rise in prevalence of hyperuricaemia was driven
by an increasing age profile, rising prevalence of CKD, or increasing burden of medical illness.
However, in an analysis that adjusted for these changing demographic and clinical profiles, the
pattern of growth persisted.
Our analysis uncovered striking differences in prevalence across representative demo-
graphic and clinical subgroups. It is noteworthy, that the highest prevalence was recorded in
elderly patients (> 80 years), which was 3-fold higher than for patients in the 18–39 age group.
Although young adults experienced the lowest prevalence of hyperuricaemia, they nevertheless
experienced a significant growth of 4.9% over the 9-year period. An equally important finding
was the observation that the prevalence of hyperuricaemia differed between men and women
across age categories. Gender differences in the prevalence of hyperuricaemia were age-depen-
dent. Among young adults, the prevalence was higher in men than in women, while in older
patients, women experienced significantly higher prevalence than men. These findings would
suggest that older women should be considered high-risk individuals for hyperuricaemia.
Patients with the poorest kidney function experienced the greatest burden of hyperuricae-
mia, highest for patients with eGFR values less than 30 ml/min/1.73m2. This is not surprising
Table 4. Odds ratio of hyperuricaemia between 2006 and 2014 in the Irish health system.
Model Observations 2006 2007 2008 2009 2010 2011 2012 2013 2014 AUC
Unadjusted 249,821 1.00 1.03
(0.99–1.07)
1.14
(1.09–1.19)
1.16
(1.11–1.21)
1.12
(1.08–1.17)
1.17
(1.12–1.22)
1.15
(1.1–1.2)
1.18
(1.13–1.23)
1.23
(1.18–1.28)
0.52
Model 1 249,821 1.00 1.02
(0.98–1.06)
1.11
(1.07–1.16)
1.12
(1.08–1.17)
1.07
(1.03–1.12)
1.11
(1.06–1.16)
1.08
(1.03–1.12)
1.09
(1.05–1.14)
1.12
(1.08–1.17)
0.60
Model 2¶ 223,591 1.00 1.01
(0.97–1.06)
1.23
(1.18–1.28)
1.22
(1.17–1.28)
1.20
(1.14–1.25)
1.25
(1.19–1.3)
1.19
(1.14–1.25)
1.21
(1.15–1.26)
1.24
(1.18–1.29)
0.68
Model 3 214,759 1.00 1.02
(0.98–1.07)
1.26
(1.21–1.32)
1.26
(1.2–1.31)
1.23
(1.17–1.28)
1.27
(1.21–1.33)
1.22
(1.16–1.27)
1.23
(1.17–1.28)
1.24
(1.19–1.3)
0.69
Model 4†† 83,096 1.00 1.07
(0.98–1.16)
1.37
(1.26–1.48)
1.38
(1.27–1.49)
1.35
(1.24–1.46)
1.47
(1.35–1.59)
1.47
(1.34–1.61)
1.34
(1.23–1.47)
1.44
(1.31–1.58)
0.74
Model 5‡‡ 28,129 1.00 1.16
(1.02–1.32)
1.58
(1.39–1.8)
1.54
(1.36–1.75)
1.61
(1.42–1.83)
1.62
(1.43–1.85)
1.55
(1.3–1.84)
1.54
(1.22–1.96)
1.50
(1.19–1.89)
0.75
Model 6† 10,404 1.00 1.20
(0.95–1.52)
1.52
(1.22–1.9)
1.55
(1.24–1.93)
1.49
(1.19–1.87)
1.58
(1.26–1.97)
1.66
(1.27–2.16)
1.49
(1.15–1.93)
1.56
(1.21–2)
0.74
 Model 1: Age group and sex adjusted.
¶ Model 2: CKD stage, age group and sex adjusted.
 Model 3: County of Residence, Location of Medical Supervision, CKD stage, age group and sex adjusted.
†† Model 4: Additional adjustment for laboratory variables including (haemoglobin, white blood cell count, total protein, albumin, potassium, serum phosphate and
calcium).
‡‡ Model 5: Model4 +additional adjustment for serum cholesterol and triglycerides.
† Model 6: Model4 +HbA1c6.5%.
https://doi.org/10.1371/journal.pone.0198197.t004
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as impaired renal clearance of sUA is a major driver of hyperuricaemia [19–21]. Moreover, the
phenotype of patients with CKD is likely to include the elderly, men, treatment with diuretics,
gout and cardiovascular conditions [9,22]. When we accounted for age, gender and several
clinical indicators of health status, we found that patients with the poorest kidney function
(GFR values < 30mls/min/1.73m2) had the highest OR of hyperuricaemia. Despite this find-
ing, our longitudinal analysis suggested that the prevalence of hyperuricaemia among patients
with the poorest kidney function did not increase over time and in fact appeared to decrease,
whereas the prevalence of hyperuricaemia increased significantly in all patients with eGFR
values> 30 ml/min/1.73m2. This would suggest that either the risk factors that give rise to
hyperuricaemia are better controlled in advanced CKD or that the use of ULT has increased
for these high-risk CKD patients.
There are few limitations in our study that deserve mention. Our analysis of prevalence was
based on estimates derived from patients within the health system and may not accurately
reflect the true prevalence in the population. We also submit that sUA is not routinely mea-
sured in clinical practice which may affect the precision of the estimates. Furthermore while
previous studies had adjusted for factors related to sUA levels (e.g. body mass index, hyperten-
sion, and diuretics) our study lacked data on these risk factors [10]. Despite these limitations,
Fig 7. Sensitivity analyses: Multivariable odds-ratio (OR) for hyperuricaemia across calendar years in the Irish health system. (A) (B) Temporal
trends in the prevalence of hyperuricaemia for sensitivity analyses 1 and 2 in men and women. (C) (D) In the multivariate model, covariates for
adjustment include: age group, sex, an interaction term between age group and sex, eGFR CKD-stage in categories, county of residence, location of
medical supervision, laboratory measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium, serum calcium and serum
phosphate concentration) and calendar year with referent 2006. P<0.001 for association of calendar year with 2006 as referent.
https://doi.org/10.1371/journal.pone.0198197.g007
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our study had several strengths. First, our dataset contained longitudinal data on all patients
within a defined health system from 2006 to 2014 with serial measurements of sUA. Measure-
ments of sUA were based on a single standardised assay across 2 regional laboratory systems
reducing the risk of measurement error. The large sample size allowed us to carefully estimate
prevalence with precision and map temporal trends in clearly defined demographic and clini-
cal subgroups. Finally, although we lacked covariates on specific clinical and medication mark-
ers, our multivariable model was able to adjust for a wide set of demographic, geographic and
laboratory measures of clinical health including kidney function.
Conclusion
We found that the burden of hyperuricaemia is substantial in the Irish health system affecting
almost a quarter of all adult men and women in 2014. We demonstrated a pattern of increasing
prevalence from 2006 to 2014 that was present for most patient subgroups across multiple set-
tings, with the exception of patients with advanced kidney impairment where a trend towards
stabilisation was observed. Prevalence estimates were highest among elderly patients and those
with severely impaired kidney function. The observed growth patterns were not accounted
for by changing demographic and clinical profiles. These findings suggest that the burden of
hyperuricaemia is increasing in the Irish health system. Given the emerging body of evidence
linking hyperuricaemia to adverse clinical outcomes, better management of uric acid and its
determinants should be a major goal.
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